Miguel Martin

Summary

Affiliation: Hospital Universitario San Carlos
Country: Spain

Publications

  1. ncbi request reprint Moving forward with capecitabine: a glimpse of the future
    Laura Biganzoli
    EORTC Investigational Drug Branch for Breast Cancer, Chemotherapy Unit, Institut Jules Bordet, Brussels, Belgium
    Oncologist 7:29-35. 2002
  2. ncbi request reprint Clinical experience with pemetrexed in breast cancer
    Miguel Martin
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Ciudad Universitaria, Madrid, Spain
    Semin Oncol 33:S15-8. 2006
  3. ncbi request reprint Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial
    Miguel Martin
    Hospital Clinico San Carlos, Madrid, Spain
    Lancet Oncol 8:219-25. 2007
  4. ncbi request reprint A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer
    Antonio Llombart-Cussac
    Hospital Universitario Arnau Vilanova, Lleida, Spain
    Clin Cancer Res 13:3652-9. 2007
  5. ncbi request reprint Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer
    Miguel Martin
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, 28040 Madrid, Spain
    Breast 16:S127-31. 2007
  6. pmc Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer
    Miguel Martin
    Medical Oncology Service, Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Universidad Complutense, Madrid, Spain
    Oncologist 18:917-23. 2013
  7. pmc PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
    Roy R L Bastien
    The ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA
    BMC Med Genomics 5:44. 2012
  8. doi request reprint Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study
    Miguel Martin
    Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Dr Esquerdo 46, Madrid 28009, Spain
    J Clin Oncol 31:2593-9. 2013
  9. pmc PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
    Miguel Martin
    Department of Medical Oncology, Instituto de Investigación Sanitaria Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain
    Breast Cancer Res Treat 138:457-66. 2013
  10. ncbi request reprint Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid
    Miguel Martin
    Complutense University and Hospital General Universitario Gregorio Maranon, Servicio de Oncologia Medica, Madrid, Spain
    Clin Cancer Res 18:4841-9. 2012

Detail Information

Publications63

  1. ncbi request reprint Moving forward with capecitabine: a glimpse of the future
    Laura Biganzoli
    EORTC Investigational Drug Branch for Breast Cancer, Chemotherapy Unit, Institut Jules Bordet, Brussels, Belgium
    Oncologist 7:29-35. 2002
    ..Confirmatory studies for many of these combinations and phase III trials versus standard therapy are now warranted...
  2. ncbi request reprint Clinical experience with pemetrexed in breast cancer
    Miguel Martin
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Ciudad Universitaria, Madrid, Spain
    Semin Oncol 33:S15-8. 2006
    ..A randomized phase II study comparing pemetrexed 600 and 900 mg/m(2) with vitamin supplementation as first-line treatment for metastatic breast cancer is ongoing...
  3. ncbi request reprint Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial
    Miguel Martin
    Hospital Clinico San Carlos, Madrid, Spain
    Lancet Oncol 8:219-25. 2007
    ..We aimed to compare the additional benefit of gemcitabine when combined with vinorelbine above that of standard vinorelbine treatment in patients with metastatic breast cancer...
  4. ncbi request reprint A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer
    Antonio Llombart-Cussac
    Hospital Universitario Arnau Vilanova, Lleida, Spain
    Clin Cancer Res 13:3652-9. 2007
    ..A secondary objective was to identify molecular biomarkers correlating with response and toxicity...
  5. ncbi request reprint Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer
    Miguel Martin
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, 28040 Madrid, Spain
    Breast 16:S127-31. 2007
    ..Therefore, the predictive value of HR status in the selection of patients for adjuvant taxane therapy is low. The predictive value of HER2 status in addition to HR status to select patients for the same purpose remains controversial...
  6. pmc Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer
    Miguel Martin
    Medical Oncology Service, Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Universidad Complutense, Madrid, Spain
    Oncologist 18:917-23. 2013
    ..Our data indicate that CTCs determined immediately before the second cycle of chemotherapy is an early and strong predictor of treatment outcome in MBC patients...
  7. pmc PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
    Roy R L Bastien
    The ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA
    BMC Med Genomics 5:44. 2012
    ..Discrepancies between these methods may lead to different treatment decisions...
  8. doi request reprint Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study
    Miguel Martin
    Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Dr Esquerdo 46, Madrid 28009, Spain
    J Clin Oncol 31:2593-9. 2013
    ..Here we tested the efficacy and safety of weekly paclitaxel (wP) in node-negative patients, which is yet to be established...
  9. pmc PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
    Miguel Martin
    Department of Medical Oncology, Instituto de Investigación Sanitaria Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain
    Breast Cancer Res Treat 138:457-66. 2013
    ..109). The PAM50 proliferation score identifies a subset of patients with a low proliferation status that may derive a larger benefit from weekly paclitaxel...
  10. ncbi request reprint Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid
    Miguel Martin
    Complutense University and Hospital General Universitario Gregorio Maranon, Servicio de Oncologia Medica, Madrid, Spain
    Clin Cancer Res 18:4841-9. 2012
    ..We evaluated further results from this study related to skeletal complications and health-related quality of life (HRQoL)...
  11. pmc Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans
    Mark Tw Ebbert
    Department of Biomedical Informatics, University of Utah, Salt Lake City, UT, USA
    J Clin Bioinforma 1:37. 2011
    ..abstract:..
  12. pmc Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer
    Miguel Martin
    Hospital Gregorio Maranon, Universidad Complutense, 28007 Madrid, Spain
    Oncologist 17:469-75. 2012
    ..The combination of bevacizumab, trastuzumab, and capecitabine was clinically active as first-line therapy for patients with HER-2-positive MBC, with an acceptable safety profile and no unexpected toxicities...
  13. doi request reprint Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer
    Miguel Martin
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Ciudad Universitaria s n, 28040 Madrid, Spain
    J Natl Cancer Inst 100:805-14. 2008
    ..Taxanes are among the most active drugs for the treatment of metastatic breast cancer, and, as a consequence, they have also been studied in the adjuvant setting...
  14. doi request reprint Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations
    Miguel Martin
    Department of Medical Oncology, San Carlos University Hospital, Madrid, Spain
    Oncologist 14:1-11. 2009
    ....
  15. doi request reprint A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer
    Miguel Martin
    Hospital Universitario San Carlos, Madrid E 28040, Spain
    Clin Breast Cancer 9:155-60. 2009
    ..A phase II trial was initiated to assess the antitumor activity and safety of pemetrexed plus doxorubicin in women with advanced breast cancer...
  16. ncbi request reprint Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer
    Miguel Martin
    Servicio de Oncologia Medica, Hospital, Universitario San Carlos, 28040 Madrid, Spain
    Womens Health (Lond Engl) 2:527-37. 2006
    ..TAC is more toxic than the traditional anthracycline-containing combinations, but many of its side effects can be ameliorated with colony-stimulating growth factor support...
  17. ncbi request reprint Prognostic and predictive factors and genetic analysis of early breast cancer
    Miguel Martin
    Department of Medical Oncology, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    Clin Transl Oncol 11:634-42. 2009
    ....
  18. ncbi request reprint Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis
    Miguel Martin
    Medical Oncology Service, Hospital Universitario San Carlos, Madrid, Spain
    Anticancer Res 29:4185-7. 2009
    ....
  19. doi request reprint Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer
    Miguel Martin
    Servicio de Oncologia Medica, Departmento de Oncología, Hospital General Universitario Gregorio Maranon, 28009 Madrid, Spain
    Breast Cancer Res Treat 123:149-57. 2010
    ..The molecular-defined subgroup of TN was clearly predictive of better response to treatment with FEC-P. Luminal A patients had the best prognosis and also have a better outcome with weekly paclitaxel...
  20. doi request reprint Adjuvant docetaxel for high-risk, node-negative breast cancer
    Miguel Martin
    Hospital General Universitario Gregorio Maranon, Madrid, Spain
    N Engl J Med 363:2200-10. 2010
    ..The value of taxanes in the treatment of node-negative disease has not been determined...
  21. doi request reprint Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study
    M Martin
    Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Ann Oncol 22:2591-6. 2011
    ....
  22. doi request reprint Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study
    Miguel Martin
    Grupo Español de Investigación en Cáncer de Mama, Madrid, Spain
    Lancet Oncol 12:369-76. 2011
    ..We aimed to determine whether treatment with motesanib plus paclitaxel is better than placebo plus paclitaxel in patients with HER2-negative locally recurrent or metastatic breast cancer...
  23. ncbi request reprint Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony sti
    M Martin
    Hospital Universitario San Carlos, Madrid, Spain
    Ann Oncol 17:1205-12. 2006
    ....
  24. ncbi request reprint Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure
    Miguel Martin
    Medical Oncology Service, Hospital Universitario San Carlos, Madrid, Spain
    Clin Breast Cancer 5:353-7. 2004
    ..The combination of pegylated liposomal doxorubicin and vinorelbine can be safely administered to patients with anthracycline-pretreated MBC and is active in this population...
  25. ncbi request reprint Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a
    M Martin
    Hospital Universitario San Carlos, Madrid, Spain
    Ann Oncol 14:833-42. 2003
    ..The purpose of this study was to determine the relative efficacy of doxorubicin versus methotrexate in combination with intravenous cyclophosphamide and 5-fluorouracil (FAC versus CMF) as adjuvant chemotherapy for operable breast cancer...
  26. ncbi request reprint Adjuvant docetaxel for node-positive breast cancer
    Miguel Martin
    Hospital Universitario San Carlos, Madrid, Spain
    N Engl J Med 352:2302-13. 2005
    ..We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer...
  27. ncbi request reprint [Epidemiological study of the GEICAM group about breast cancer in Spain (1990-1993): El Alamo project]
    Miguel Martin
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Med Clin (Barc) 122:12-7. 2004
    ....
  28. ncbi request reprint Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines
    M Martin
    Hospital Universitario San Carlos, Madrid, Spain
    Ann Oncol 14:1246-52. 2003
    ..To assess antitumor activity and toxicity of pemetrexed in metastatic breast cancer (MBC) patients previously treated with anthracyclines...
  29. ncbi request reprint The "El Alamo" project (1990-1997): two consecutive hospital-based studies of breast cancer outcomes in Spain
    M Martin
    Hospital Clinico Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 8:508-18. 2006
    ..The "Alamo" project is a retrospective analysis of 14,854 patients diagnosed of breast cancer between 1990 and 1997 in 50 Spanish hospitals...
  30. ncbi request reprint Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study
    Emilio Alba
    Medical Oncology Department, Complejo Hospitalario Virgen de la Victoria, Malaga, Spain
    J Clin Oncol 22:2587-93. 2004
    ....
  31. doi request reprint Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register
    Javier Puente
    Medical Oncology Department, Hospital Clinico San Carlos, c Martin Lagos s n, 28040, Madrid, Spain
    Breast Cancer Res Treat 122:591-600. 2010
    ..61). The median survivals for these groups were 3.69, 2.27 and 1.02 years, respectively (P < 0.0001). In conclusion, risk scores are extraordinarily valuable tools, highly recommendable in the clinical practice...
  32. ncbi request reprint Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer
    José A García-Sáenz
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
    Clin Breast Cancer 6:325-9. 2005
    ..To determine the activity of successive trastuzumab-containing regimens in HER2-overexpressing metastatic breast cancer (MBC) as well as the response rate (RR), time to progression (TTP), and predictive factors for response...
  33. doi request reprint Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study
    Emilio Alba
    Department of Medical Oncology, Hospital Clinico Universitario Virgen de la Victoria, 29010 Malaga, Spain
    Breast Cancer Res Treat 122:169-76. 2010
    ..This phase III trial demonstrated that maintenance chemotherapy with PLD is well tolerated and offers improved TTP in patients with MBC following first-line chemotherapy...
  34. ncbi request reprint Time-to-progression in breast cancer: a stratification model for clinical trials
    Juan de la Haba-Rodriguez
    Servicio de Oncologia Medica, Complejo Hospitalario Reina Sofía, Cordoba, Spain
    Breast 17:239-44. 2008
    ..This can be a useful tool at the time of selecting and stratifying patients on entry into new randomised clinical trials...
  35. ncbi request reprint Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007
    Juan de la Haba-Rodriguez
    Medical Oncology Department, Hospital Universitario Reina Sofia, Cordoba, Spain
    Clin Transl Oncol 10:552-9. 2008
    ..In view of these important changes, opinions on some specific aspects may be varied and all are justified. This document represents a review of the current state of the evidence...
  36. doi request reprint Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma
    Javier Puente
    Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Anticancer Drugs 21:S19-22. 2010
    ..In July 2008, trastuzumab monotherapy was resumed and since then no cardiac events have been reported, while maintaining a radiological and clinical response...
  37. ncbi request reprint Molecular biology of breast cancer
    Miguel Martin
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 8:7-14. 2006
    ..3. Prediction of response to diverse antitumoral treatments. 4. Identification of molecular targets that allows the development of new tailored antitumor treatments...
  38. doi request reprint Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer
    Juan de la Haba-Rodriguez
    Servicio de Oncologia Medica, Hospital Universitario Reina Sofia, Avda Menendez Pidal s n, 14005 Córdoba, Spain
    Breast Cancer Res Treat 125:273-8. 2011
    ..Myalgias and secondary sensory neuropathy to paclitaxel were recorded more frequently during autumn. Climate should be considered a significant variable in toxicity to chemotherapy...
  39. ncbi request reprint Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer
    Antonio Anton
    Medical Oncology Service, University Hospital Miguel Servet, Avda Isabel La Catolica 1 3, 50009 Zaragoza, Spain
    Anticancer Res 30:2255-61. 2010
    ..To determine the recommended doses of oral vinorelbine (VN) and capecitabine (C) in metastatic breast cancer...
  40. doi request reprint Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review
    José A García-Sáenz
    Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 13:121-32. 2011
    ..Suboptimal survival results have led to major efforts to identify prognostic factors, improve surgical staging and develop adjuvant therapies to improve patients' outcomes...
  41. doi request reprint A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer
    Miguel Martin
    Hospital Universitario Gregorio Maranon, Universidad Complutense, Calle de Maiquez 7, 28009 Madrid, Spain
    Eur J Cancer 49:3763-72. 2013
    ....
  42. doi request reprint Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?
    Atocha Romero
    Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 14:163-8. 2012
    ..However, results are not conclusive. In this paper, we review some of the published studies addressing the predictive value of TOP2A as well as the cellular functions of this enzyme and its status in breast cancer tissue...
  43. doi request reprint A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome
    Daniela Caronia
    Human Genotyping Unit CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain
    Clin Cancer Res 17:2006-13. 2011
    ..We investigated the association between grade 3 HFS and genetic variations in genes involved in capecitabine metabolism...
  44. ncbi request reprint Circulating tumour cells in locally advanced breast cancer
    Jose Angel Garcia-Saenz
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 11:544-7. 2009
    ..Two blood samples were obtained from 72 eligible LABC patients to isolate and enumerate CTCs before neoadjuvant chemotherapy started on day 1, and on day 21, immediately before second cycle administration...
  45. ncbi request reprint Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group
    Carlos Jara-Sánchez
    Unidad de Oncología Médica, Fundacion Hospital Alcorcon, Madrid, Spain
    Clin Breast Cancer 3:399-404. 2003
    ..However, the results do not indicate clear advantages compared to the conventional weekly scheme of administration...
  46. ncbi request reprint Circulating tumor cells in solid tumor in metastatic and localized stages
    Luisa M Maestro
    Servicio de Analisis Clinicos, Hospital Clinico San Carlos, 28040, Madrid, Espana
    Anticancer Res 29:4839-43. 2009
    ..The aim of this study was the detection of circulating tumor cells (CTC) in three tumor types of epithelial origin...
  47. doi request reprint Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials
    Pilar García Alfonso
    Medical Oncology Service, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    Onkologie 36:363-7. 2013
    ....
  48. pmc Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization
    Atocha Romero
    Department of Medical Oncology, Hospital Clinico San Carlos, Madrid, Spain
    Am J Pathol 178:1453-60. 2011
    ..All of these features should be taken into consideration when assessing the predictive value of TOP2A for anthracycline-based chemotherapy...
  49. doi request reprint Neratinib (HKI-272) in the treatment of breast cancer
    Sara Lopez-Tarruella
    Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Calle Dr Esquerdo 46, 28007, Madrid, Spain
    Future Oncol 8:671-81. 2012
    ..The potential combinations of neratinib with chemotherapy in the metastatic, adjuvant and even neoadjuvant settings are appraised. These results and future perspectives will be discussed...
  50. doi request reprint Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial
    Antonio Llombart-Cussac
    Medical Oncology Service, Biomedical Research Institute, Arnau de Vilanova University Hospital, Lleida, Spain
    Cancer 118:241-7. 2012
    ..In the current study, the authors formally evaluated the activity of anastrozole and exemestane in postmenopausal women with hormone-responsive, advanced breast cancer...
  51. pmc Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes
    Marta Dueñas
    Molecular Oncology Unit, CIEMAT, Madrid, Spain
    PLoS ONE 7:e42494. 2012
    ..The results also provide new targets for the treatment of p53-defective tumours...
  52. pmc Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer
    Sara Lopez-Tarruella
    Medical Oncology Department, Clinico San Carlos Hospital, Madrid, Profesor Martin Lagos, Madrid, Spain
    Breast Cancer Res 11:204. 2009
    ..In this review we focus on some of the current controversies and potential future steps in adjuvant chemotherapy for treatment of early breast cancer...
  53. ncbi request reprint Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
    Joan Albanell
    Medical Oncology Department, Hospital del Mar IMAS and Cancer Research Program, ES 08003 Barcelona, Spain
    Clin Transl Oncol 11:363-75. 2009
    ....
  54. pmc Differences in the therapeutic approach to colorectal cancer in young and elderly patients
    José A Serra-Rexach
    Department of Geriatric Medicine, Hospital General Universitario Gregorio Maranon, Doctor Esquerdo 46, 28007 Madrid, Spain
    Oncologist 17:1277-85. 2012
    ..To analyze differences in the therapeutic approach to and tumor-related mortality of young and elderly colorectal cancer (CRC) patients...
  55. doi request reprint Family history record and hereditary cancer risk perception according to National Cancer Institute criteria in a Spanish medical oncology service: a retrospective study
    Iván Márquez-Rodas
    Servicio de Oncologia Medica, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    Oncology 82:30-4. 2012
    ..However, the large number of hereditary syndromes makes it difficult to take them all into account in daily practice. Consequently, the National Cancer Institute (NCI) has suggested a series of criteria to guide initial suspicion...
  56. ncbi request reprint Molecular haplotyping of tandem single nucleotide polymorphisms by allele-specific PCR
    Carmen Cañadas
    Laboratorio de Oncología Molecular y Servicio de Oncología Médica, Hospital Clinico San Carlos, 28040 Madrid, Spain
    Anal Biochem 364:153-8. 2007
    ..In addition, we suggest that tandem SNPs are potentially interesting polymorphic markers in which molecular haplotyping can be performed easily...
  57. ncbi request reprint Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer
    Eva Thomas
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 25:3399-406. 2007
    ..This international phase II trial assessed the activity of ixabepilone in patients with metastatic breast cancer (MBC) that was resistant to taxane therapy...
  58. ncbi request reprint Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer
    Miguel Martin
    JAMA 294:2166; author reply 2166-7. 2005
  59. ncbi request reprint Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial
    Jean Marc Nabholtz
    University of California at Los Angeles, CA 90095 7077, USA
    J Clin Oncol 21:968-75. 2003
    ..This randomized, multicenter, phase III study compared doxorubicin and docetaxel (AT) with doxorubicin and cyclophosphamide (AC) as first-line chemotherapy (CT) in metastatic breast cancer (MBC)...
  60. doi request reprint Docetaxel-related side effects and their management
    Jackie Baker
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Eur J Oncol Nurs 12:253-68. 2008
    ..It is therefore important to share and build on experiences, through research and discussion, to maximise the healthcare professional's ability to offer the best standard of care to patients...
  61. doi request reprint Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis
    Fabrice Andre
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:2636-43. 2008
    ..The aim of the present study was to assess the efficacy of adjuvant docetaxel and anthracycline therapy according to ER expression in two randomized clinical trials...
  62. doi request reprint The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients
    Christoph C Zielinski
    Department of Medicine I and Clinical Division of Oncology, Medical University Vienna and Central European Cooperative Oncology Group CECOG, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Eur J Cancer 44:353-65. 2008
    ..Any formulation of G-CSF is recommended. The utility of G-CSF in reducing the incidence of FN and enabling treatment regimens is discussed...
  63. ncbi request reprint The global breast cancer burden: variations in epidemiology and survival
    Gabriel N Hortobagyi
    The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Clin Breast Cancer 6:391-401. 2005
    ..This will aid the development of tailored strategies to improve outcomes in general as well as the standard of care for underserved populations and reduce the burden of breast cancer worldwide...